[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100598477":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":11,"centralContacts":29,"locations":38,"responsibleParty":102,"collaborators":106,"id":115,"slug":116,"hasResults":117,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":11,"eligibilityCriteria":121,"healthyVolunteers":117,"sex":122,"minAge":123,"maxAge":124,"enrollmentInfo":125,"targetDuration":11,"studyType":128,"phases":129,"briefSummary":131,"conditions":132,"keywords":134,"overallStatus":137,"whyStopped":11,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":147},{"fullName":5,"class":6},"Sun Yat-sen University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Reduced delineation arm","EXPERIMENTAL",null,[13],"Radiation: reduced CTV delineation",{"label":15,"type":16,"description":11,"interventionNames":17},"Standard delineation arm","ACTIVE_COMPARATOR",[18],"Radiation: standard CTV delineation",[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":11},"RADIATION","standard CTV delineation","The anterior border of CTV2 is delineated at the posterior 1\u002F3 of the nasal cavity.",[15],{"type":21,"name":26,"description":27,"armGroupLabels":28,"otherNames":11},"reduced CTV delineation","The anterior border of CTV2 is defined as 5 mm anterior to the posterior nasal cavity anteriorly from the choanae.",[9],[30,35],{"name":31,"role":32,"phone":33,"phoneExt":11,"email":34},"Hai-Qiang Mai, Dr.","CONTACT","+8602087343380","maihq@sysucc.org.cn",{"name":36,"role":32,"phone":33,"phoneExt":11,"email":37},"Qiu-Yan Chen, Dr.","chenqy@sysucc.org.cn",[39,56,68,76,89],{"facility":40,"status":11,"city":41,"state":42,"zip":11,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"First People's Hospital of Foshan","Foshan","Guangdong","China","CN",{"type":46,"coordinates":47},"Point",[48,49],113.13148,23.02677,{"lat":49,"lon":48},[52],{"name":53,"role":32,"phone":54,"phoneExt":11,"email":55},"Ning Zhang","+86075783833633","zning@fsyyy.com",{"facility":57,"status":11,"city":58,"state":42,"zip":11,"country":43,"countryCode":44,"cosmosGeoPoint":59,"geoPoint":63,"contacts":64},"Sun Yat-sen University Cancer Center","Guangzhou",{"type":46,"coordinates":60},[61,62],113.25,23.11667,{"lat":62,"lon":61},[65,67],{"name":66,"role":32,"phone":33,"phoneExt":11,"email":37},"Qiu-yan Chen, Dr.",{"name":36,"role":32,"phone":11,"phoneExt":11,"email":37},{"facility":69,"status":11,"city":70,"state":42,"zip":11,"country":43,"countryCode":44,"cosmosGeoPoint":11,"geoPoint":11,"contacts":71},"Affiliated Hospital of Guangdong Medical University","Zhangjiang",[72],{"name":73,"role":32,"phone":74,"phoneExt":11,"email":75},"Haiqing Luo","+8607592369336","hqluo@126.com",{"facility":77,"status":11,"city":78,"state":79,"zip":11,"country":43,"countryCode":44,"cosmosGeoPoint":80,"geoPoint":84,"contacts":85},"The Fourth Affiliated Hospital of Guangxi Medical University","Liuzhou","Guangxi",{"type":46,"coordinates":81},[82,83],109.40698,24.32405,{"lat":83,"lon":82},[86],{"name":87,"role":32,"phone":88,"phoneExt":11,"email":11},"Ying Lu","+8607723111580",{"facility":90,"status":11,"city":91,"state":79,"zip":11,"country":43,"countryCode":44,"cosmosGeoPoint":92,"geoPoint":96,"contacts":97},"Wuzhou Red Cross Hospital","Wuzhou",{"type":46,"coordinates":93},[94,95],111.28848,23.48054,{"lat":95,"lon":94},[98],{"name":99,"role":32,"phone":100,"phoneExt":11,"email":101},"Jinhui Liang","+8607745812345","566jv@sina.cn",{"type":103,"investigatorFullName":104,"investigatorTitle":105,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"SPONSOR_INVESTIGATOR","Hai-Qiang Mai,MD,PhD","Professor",[107,108,109,112,113],{"name":40,"class":6},{"name":69,"class":6},{"name":110,"class":111},"The Wuzhou Red Cross Hospital","UNKNOWN",{"name":77,"class":111},{"name":114,"class":111},"Zhongshan City People 's Hospital","100598477","phase-3-shrinking-the-anterior-border-of-ctv2-for-nasopharyngeal-carcinoma-to-reduce-the-radiation-of-nasal-cavity-100598477",false,"NCT07072000","Shrinking the Anterior Border of CTV2 for Nasopharyngeal Carcinoma to Reduce the Radiation of Nasal Cavity","Shrinking the Anterior Border of CTV2 for Nasopharyngeal Carcinoma to Reduce the Radiation of Nasal Cavity : an Open-label, Non-inferiority, Multicenter, Randomized Phase III Trial","Inclusion Criteria:\n\n1. Newly diagnosed, histologically confirmed non-keratinizing carcinoma (WHO classification).\n2. Stage I-III disease (AJCC 9th edition).\n3. Tumor extends to nasal cavity (including nasal septum).\n4. No distant metastasis (M0).\n5. Age 18-70 years.\n6. Male or non-pregnant female.\n7. Scheduled for radiotherapy.\n8. ECOG performance status 0-1 .\n9. Adequate bone marrow function: white blood cells \\>4×10⁹\u002FL, hemoglobin \\>90 g\u002FL, platelets \\>100×10⁹\u002FL.\n10. Normal hepatic\u002Frenal function: total bilirubin ≤1.5×ULN, AST\u002FALT ≤2.5×ULN, alkaline phosphatase ≤2.5×ULN, creatinine clearance ≥60 mL\u002Fmin.\n11. Written informed consent obtained.\n\nExclusion Criteria:\n\n1. Keratinizing squamous cell carcinoma (WHO Type I) or basaloid squamous cell carcinoma.\n2. Age \\\u003C18 or \\>70 years.\n3. Recurrent disease or distant metastasis.\n4. No tumor extension into the nasal cavity (including the nasal septum).\n5. Prior malignancy (except adequately treated basal\u002Fsquamous cell skin cancer or cervical carcinoma in situ).\n6. Pregnancy\u002Flactation (premenopausal women require pregnancy test; effective contraception mandated).\n7. Prior radiotherapy (except non-melanoma skin cancer with lesions outside current portals).\n8. Preoperative chemotherapy or surgical resection of primary\u002Fneck lesions (excluding diagnostic procedures).\n9. Severe coexisting illness.","ALL","18 Years","70 Years",{"count":126,"type":127},550,"ESTIMATED","INTERVENTIONAL",[130],"PHASE3","This is a an open-label, non-inferiority, multicenter, randomized phase III trial aimed to explore the efficacy and safety of shrinking the anterior border of CTV2 in nasopharyngeal carcinoma patients without tumor invasion into the posterior nasal aperture.",[133],"Nasopharyngeal Cancinoma (NPC)",[135,136],"nasopharyngeal carcinoma","radiotherapy","NOT_YET_RECRUITING","2025-07-16",{"date":140,"type":141},"2025-07-18","ACTUAL",{"date":143,"type":127},"2025-08-01",{"date":145,"type":127},"2032-07-31",{"name":104,"class":6},5]